Introducing GPT-Rosalind for life sciences research

Update on September 11, 2026: GPT‑Rosalind, our specialized model for life sciences research, is coming out of research preview and is now available globally to eligible organizations through our trusted-access program. All eligible organizations will continue to get access to the latest Rosalind models as they’re released. Published pricing will take effect on October 5, 2026. Review GPT‑Rosalind pricing⁠⁠(opens in a new window).

Today, we’re introducing GPT‑Rosalind, our frontier reasoning model built to support research across biology, drug discovery, and translational medicine. The life sciences model series is optimized for scientific workflows, combining improved tool use with deeper understanding across chemistry, protein engineering, and genomics.

On average, it takes roughly 10 to 15 years to go from target discovery to regulatory approval for a new drug in the United States. Gains made at the earliest stages of discovery compound downstream in better target selection, stronger biological hypotheses and higher-quality experiments. Progress in the life sciences is constrained not only by the difficulty of the underlying science, but by the complexity of the research workflows themselves. Scientists must work across large volumes of literature, specialized databases, experimental data, and evolving hypotheses in order to generate and evaluate new ideas. These workflows are often time-intensive, fragmented, and difficult to scale.

GPT‑Rosalind is available in ChatGPT, Codex, and the API for qualified customers through our trusted access program. We’re also introducing a freely accessible Life Sciences research plugin for Codex, helping scientists connect models to over 50 scientific tools and data sources. We are working with customers like Amgen, Moderna, the Allen Institute, Thermo Fisher Scientific, and others to apply GPT‑Rosalind across workflows that accelerate research and discovery.